Nutrients in eggs help lower risk of type 2 diabetes
the ONA take:
Nutrition research has increasingly focused on the health effects of whole foods and diets, as opposed to focusing on individual nutrients.
This shift may help to dispel the egg’s poor reputation as a healthy food. New research from the University of Eastern Finland found that egg consumption may reduce the risk of type 2 diabetes.
Eggs have many beneficial nutrients that can impact glucose metabolism and low-grade inflammation, which lower the risk of type 2 diabetes.
In this study, the dietary habits of 2,332 men ages 42 to 60 years were assessed at baseline of the Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD).
During follow-up of 19.3 years, type 2 diabetes was diagnosed in 432 men. Men who ate approximately four eggs per week had a 37% lower risk of type 2 diabetes than men who only ate approximately one egg per week.
This association persisted even after possible confounding factors were taken into consideration. Consuming more than four eggs per week, however, did not provide any additional benefits.
Egg consumption may reduce the risk of type 2 diabetes.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|